CNBC reported on 4 August 2026 that Procter & Gamble has agreed to acquire Thorne, a practitioner-channel supplement brand, from L Catterton for $3.8 billion in cash. Source: https://www.cnbc.com/2026/08/04/procter-gamble-will-acquire-supplements-brand-thorne.html, with same-day coverage from Bloomberg, WWD, Happi and NutraIngredients. Close is expected in Q4 2026.
The numbers behind the price are worth stating. Thorne was founded in 1984. It surpassed $500 million in revenue in 2025 and is on pace for $650 million in 2026. A majority of its revenue comes from shoppers under 40. It listed publicly in late 2021 at a $525 million valuation, was taken private by L Catterton in 2023 for $680 million, and is now changing hands at $3.8 billion.
P&G already owns Metamucil, Align, New Chapter, Oral-B and Vicks. This is not a company discovering wellness. It is a company deciding the category is worth considerably more than it was three years ago.
What is actually being bought
The lazy read is that supplements are trending and P&G wanted in. That does not explain the price.
What a business like Thorne has, and what most beauty ranges do not, is consumption frequency with a fixed clock. A supplement is consumed daily. A bottle runs out on a predictable date. The customer either reorders or stops, and the decision recurs every thirty or sixty days without any need to re-persuade them that the category exists.
That produces revenue with a shape acquirers pay a premium for. Predictable. Compounding. Low incremental acquisition cost per pound of revenue after the first purchase. Subscription-grade retention without necessarily requiring a subscription.
Compare that to a serum with a six-month usage life, bought by a customer who may well try something else before the bottle is empty, in a category where novelty is part of the appeal. Same customer, same bathroom, completely different revenue profile.
P&G is not paying $3.8 billion for pills. It is paying for the reorder behaviour attached to them.
The wrong lesson to take from this
The tempting conclusion for a founder at £500k-£5m is to add an ingestible. A collagen powder, a skin supplement, a gummy. It looks like a way to buy the same characteristics for the cost of a contract manufacturer.
It is usually a mistake at this size, for reasons that have nothing to do with whether the product is good.
An ingestible is a different regulatory category. In the UK and EU it moves you into food supplement rules, with their own permitted-claims framework, their own labelling requirements, and a very short list of health claims you are actually allowed to make. Most of the things a beauty founder would naturally want to say about a skin supplement are not authorised claims, and the gap between what makes the product sellable and what you are permitted to print is where brands get into trouble.
It also changes your risk profile. Ingestibles carry consumer safety exposure that topicals do not, along with different insurance, different supplier due diligence, and different recall implications.
And it rarely solves the problem founders think it solves. A new SKU in a new category does not fix weak retention in your existing range. It adds a second thing with weak retention.
The transferable version
The characteristic worth copying is replenishment predictability, and you can engineer more of it into products you already sell.
Start by knowing your actual cycle. For each of your top SKUs, how many days of use does the pack contain at the directed usage? Most founders have never calculated this, which means they have never checked whether their marketing cadence matches the moment a customer runs out.
Then measure the reorder rate against that window. Of the customers who bought your hero product, what share bought again within one and a half times its usage life? That single number tells you more about the health of your business than almost anything on your dashboard, and it is the number an acquirer would look at.
If the answer is poor, the fixes are unglamorous and they work. Time your email and SMS to the run-out date rather than to a marketing calendar. Make pack sizes match a sensible routine rather than a price point. Reduce the number of first-purchase options so the second purchase is an obvious repeat rather than a new decision. Give a genuine reason to stay on the same product rather than rotating.
None of that requires a new category, new compliance work, or new capital.
What this says about exits
There is a second signal in this deal, and it is more relevant to founders than the category read.
Thorne went from a $680 million take-private in 2023 to $3.8 billion in 2026. Part of that is growth. Part of it is that the acquirer universe for beauty-adjacent wellness widened considerably in that period, and competitive tension raises prices.
For a founder building toward an eventual sale, the practical implication is that the buyer for your business may not be a beauty company. It may be a CPG group, a wellness platform, or a strategic in an adjacent category who values your customer relationship rather than your formulation.
That should shape what you keep clean along the way. Customer data you actually own and can show. Retention cohorts you can produce on request. Claims that are substantiated and documented. Formulation and supplier records that survive scrutiny. Those are the things that hold up in diligence regardless of who the buyer turns out to be.
The honest summary
A $3.8 billion price for a supplement brand is a genuine signal that the line between beauty and wellness has stopped being a line at the top of the market.
It is not an instruction to launch an ingestible. For most brands at £500k-£5m, the same underlying advantage is available by making the products you already sell easier to run out of, easier to reorder, and harder to drift away from. That is a less exciting project than a new category, and it is considerably more likely to still be working in two years.